CoChat

PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin

Open access
Besse-Patin, Aurèle, Jeromson, Stewart, Levesque-Damphousse, Philipa, Secco, Blandine, Laplante, Mathieu, Estall, Jennifer L. · 2019 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Significance: The liver plays crucial roles in the control of glucose homeostasis during the fast-feeding cycle. It responds to insulin and glucagon to either store or provide glucose to other organs. Insulin resistance is a hallmark of metabolic diseases such as type 2 diabetes and nonalcoholic fatty liver disease. Associations have been made between low hepatic levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1A) and hepatic insulin resistance, but underlying mechanisms are elusive. We show that PGC1A controls the hepatic ratio of Insulin Receptor Substrates 1 (IRS1) and IRS2 expression, crucial for defining the precise insulin signal in hepatocytes to respond to fasting and feeding. Importantly, PGC1A is key for insulin-mediated suppression of hepatic glucose production.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1815150116

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. PGC1A levels influence insulin-stimulated AKT phosphorylation. Immunoblots of protein from primary mouse hepatocytes treated with 100 nM insulin for 15 min (or indicated time). Insulin-signaling pathway activation in hepatocytes from (A and D) male WT and LH (liver-PGC1A heterozygote) and LKO (liver-PGC1A knockout) mice. (B and E) Hepatocytes infected with adenoviruses expressing vector control (AdCTL) or PGC1A or (C) liver-specific PGC1A and PGC1B double-knockout mice (LA/BKO). All experiments were performed at least two times, and each lane represents an individual mouse.
Fig. 1. PGC1A levels influence insulin-stimulated AKT phosphorylation. Immunoblots of protein from primary mouse hepatocytes treated with 100 nM insulin for 15 min (or indicated time). Insulin-signaling pathway activation in hepatocytes from (A and D) male WT and LH (liver-PGC1A heterozygote) and LKO (liver-PGC1A knockout) mice. (B and E) Hepatocytes infected with adenoviruses expressing vector control (AdCTL) or PGC1A or (C) liver-specific PGC1A and PGC1B double-knockout mice (LA/BKO). All experiments were performed at least two times, and each lane represents an individual mouse.CC BY-NC-ND · PubMed Central
Fig. 2. PGC1A levels affect gene expression of key members of the insulin-signaling pathway. Gene expression by qPCR in primary mouse hepatocytes. WT cells infected with adenovirus overexpressing (A) PGC1A, (B) PGC1B, or (C) primary hepatocytes isolated from LA/BKO mice. Experiments were performed at least twice with n = 4 ± SEM *P < 0.05 vs. control.
Fig. 2. PGC1A levels affect gene expression of key members of the insulin-signaling pathway. Gene expression by qPCR in primary mouse hepatocytes. WT cells infected with adenovirus overexpressing (A) PGC1A, (B) PGC1B, or (C) primary hepatocytes isolated from LA/BKO mice. Experiments were performed at least twice with n = 4 ± SEM *P < 0.05 vs. control.CC BY-NC-ND · PubMed Central
Fig. 3. PGC1A regulates IRS protein expression. Immunoblots of protein from primary hepatocytes treated 15 min with 100 nM insulin. (A) Cells overexpressing vector control (CTL), PGC1A, or PGC1B. (B) Cells from LA/BKO mice. (C) Ratio of p-AKT to t-AKT in cells overexpressing PGC1A or PGC1B (n = 4 ± SEM, performed at least two times).
Fig. 3. PGC1A regulates IRS protein expression. Immunoblots of protein from primary hepatocytes treated 15 min with 100 nM insulin. (A) Cells overexpressing vector control (CTL), PGC1A, or PGC1B. (B) Cells from LA/BKO mice. (C) Ratio of p-AKT to t-AKT in cells overexpressing PGC1A or PGC1B (n = 4 ± SEM, performed at least two times).CC BY-NC-ND · PubMed Central
Fig. 4. PGC1A potentiates glucagon-stimulated IRS2 expression through CREB. Primary mouse hepatocytes treated with 40 nM glucagon or vehicle. (A) Gene expression (n = 4 ± SE) and (B) immunoblots from cells expressing shControl or shPGC1A. (B, Right) Quantification of two experiments (n = 5 ± SEM). (C) Immunoblot from hepatocytes coexpressing vector control (CTL) or dominant-negative CREB (C-DN or CREBDN), dominant-negative TCF4 (T-DN or TCF4DN), or PGC1A, as indicated. (Right) Quantification of two experiments (n = 5 ± SEM). (D) mRNA in primary hepatocytes expressing CREB DN or Control vector. (E) Immunoblots from primary hepatocytes pretreated or not with glucagon (40 nM, 4 h) and treated with insulin (100 nM, 15 min). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. control. Blots are representative of two independent experiments. A.U., arbitrary units; Glg, glucagon; veh, vehicle.
Fig. 4. PGC1A potentiates glucagon-stimulated IRS2 expression through CREB. Primary mouse hepatocytes treated with 40 nM glucagon or vehicle. (A) Gene expression (n = 4 ± SE) and (B) immunoblots from cells expressing shControl or shPGC1A. (B, Right) Quantification of two experiments (n = 5 ± SEM). (C) Immunoblot from hepatocytes coexpressing vector control (CTL) or dominant-negative CREB (C-DN or CREBDN), dominant-negative TCF4 (T-DN or TCF4DN), or PGC1A, as indicated. (Right) Quantification of two experiments (n = 5 ± SEM). (D) mRNA in primary hepatocytes expressing CREB DN or Control vector. (E) Immunoblots from primary hepatocytes pretreated or not with glucagon (40 nM, 4 h) and treated with insulin (100 nM, 15 min). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. control. Blots are representative of two independent experiments. A.U., arbitrary units; Glg, glucagon; veh, vehicle.CC BY-NC-ND · PubMed Central
Fig. 5. Insulin-induced suppression of hepatocyte gluconeogenesis is regulated by the PGC1A/IRS2 axis in vitro and in vivo. (A) Insulin-mediated (100 nM, 1 h) suppression of glucagon-induced (1 nM, 1 h) gluconeogenesis (GNG) in primary hepatocytes overexpressing vector, IRS1, or IRS2 (n = 8 ± SEM). *P < 0.05 vs. Control; #P < 0.05 IRS2 vs. IRS1. (B) Insulin suppression of GNG in WT and LA/BKO hepatocytes expressing control or PGC1A and shControl or shIRS2, as indicated (n = 4 ± SEM). ###P < 0.001 vs. WT; *P < 0.05, ***P < 0.001. Male mice tail-vein–injected with viruses encoding vector (AdCTL) or PGC1A (AdPGC1A). Blood glucose (C) and plasma insulin (D) measured after 16 h fasting or 1 h refeeding. (E) Pyruvate tolerance test and area under the curve (Right). n = 9 ± SEM; *P < 0.05 vs. control. All experiments were performed twice.
Fig. 5. Insulin-induced suppression of hepatocyte gluconeogenesis is regulated by the PGC1A/IRS2 axis in vitro and in vivo. (A) Insulin-mediated (100 nM, 1 h) suppression of glucagon-induced (1 nM, 1 h) gluconeogenesis (GNG) in primary hepatocytes overexpressing vector, IRS1, or IRS2 (n = 8 ± SEM). *P < 0.05 vs. Control; #P < 0.05 IRS2 vs. IRS1. (B) Insulin suppression of GNG in WT and LA/BKO hepatocytes expressing control or PGC1A and shControl or shIRS2, as indicated (n = 4 ± SEM). ###P < 0.001 vs. WT; *P < 0.05, ***P < 0.001. Male mice tail-vein–injected with viruses encoding vector (AdCTL) or PGC1A (AdPGC1A). Blood glucose (C) and plasma insulin (D) measured after 16 h fasting or 1 h refeeding. (E) Pyruvate tolerance test and area under the curve (Right). n = 9 ± SEM; *P < 0.05 vs. control. All experiments were performed twice.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 124

Metadata

Authors
Besse-Patin, A., Jeromson, S., Levesque-Damphousse, P., Secco, B., Laplante, M., & Estall, J. L.
Affiliations
  • Institut de Recherches Cliniques de Montréal (IRCM), Montreal, QC, Canada H2W 1R7;
  • Montreal Clinical Research Institute (CA)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
Corresponding author
Estall, Jennifer L.
Venue
Proceedings of the National Academy of Sciences
Published
2019-02-15
Volume
116
Issue
10
Pages
4285-4290
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2913974217
Cited by
124
References
46
Citations by year
2026: 9 · 2025: 20 · 2024: 20 · 2023: 17 · 2022: 12 · 2021: 21 · 2020: 22 · 2019: 3
FWCI
4.80
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Gouvernement du Canada | Canadian Institutes of Health Research (SVB-145591)
  • Fonds de Recherche du Québec - Santé (35208)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
PGC-1α, IRS-1, insulin receptor substrate 2, insulin signaling, hepatic gluconeogenesis, fasting, glucagon signaling, CREB, Akt, glucose homeostasis, insulin resistance, hepatocytes, non-alcoholic fatty liver disease, type 2 diabetes, cyclic AMP
MeSH terms
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Animals, Diabetes Mellitus, Type 2, Fasting, Female, Gene Expression Regulation, Glucagon, Gluconeogenesis, Glucose, Homeostasis, Humans, Insulin, Insulin Resistance, Liver, Liver Diseases, Male, Signal Transduction, Cyclic AMP Response Element-Binding Protein, Hepatocytes, Models, Animal, Proto-Oncogene Proteins c-akt, Mice, Insulin Receptor Substrate Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin. https://app.cochat.ai/papers/10.1073/pnas.1815150116
The paper
Besse-Patin, A., Jeromson, S., Levesque-Damphousse, P., Secco, B., Laplante, M., & Estall, J. L. (2019). PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1815150116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.